Pfizer Inc (PFE)
27.78
+0.19
(+0.69%)
USD |
NYSE |
Mar 27, 16:00
27.82
+0.04
(+0.14%)
Pre-Market: 05:53
Pfizer Enterprise Value: 215.30B for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 215.30B |
March 26, 2024 | 214.22B |
March 25, 2024 | 213.32B |
March 22, 2024 | 212.92B |
March 21, 2024 | 214.62B |
March 20, 2024 | 214.84B |
March 19, 2024 | 214.45B |
March 18, 2024 | 214.96B |
March 15, 2024 | 216.20B |
March 14, 2024 | 217.27B |
March 13, 2024 | 217.78B |
March 12, 2024 | 216.60B |
March 11, 2024 | 218.63B |
March 08, 2024 | 212.13B |
March 07, 2024 | 209.71B |
March 06, 2024 | 211.96B |
March 05, 2024 | 205.70B |
March 04, 2024 | 204.62B |
March 01, 2024 | 208.58B |
February 29, 2024 | 208.41B |
February 28, 2024 | 211.12B |
February 27, 2024 | 210.27B |
February 26, 2024 | 211.91B |
February 23, 2024 | 215.18B |
February 22, 2024 | 214.00B |
Date | Value |
---|---|
February 21, 2024 | 214.68B |
February 20, 2024 | 214.22B |
February 16, 2024 | 214.39B |
February 15, 2024 | 213.77B |
February 14, 2024 | 211.49B |
February 13, 2024 | 210.70B |
February 12, 2024 | 214.60B |
February 09, 2024 | 214.03B |
February 08, 2024 | 214.09B |
February 07, 2024 | 214.03B |
February 06, 2024 | 213.69B |
February 05, 2024 | 208.44B |
February 02, 2024 | 210.48B |
February 01, 2024 | 212.51B |
January 31, 2024 | 211.32B |
January 30, 2024 | 210.98B |
January 29, 2024 | 213.58B |
January 26, 2024 | 213.52B |
January 25, 2024 | 213.52B |
January 24, 2024 | 218.38B |
January 23, 2024 | 218.94B |
January 22, 2024 | 218.27B |
January 19, 2024 | 218.10B |
January 18, 2024 | 217.03B |
January 17, 2024 | 217.36B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
248.59B
Average
244.77B
Median
Enterprise Value Benchmarks
Amgen Inc | 207.11B |
Gilead Sciences Inc | 108.59B |
Johnson & Johnson | 386.89B |
Viking Therapeutics Inc | 8.013B |
Moderna Inc | 33.75B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -3.369B |
Revenue (Quarterly) | 14.25B |
Total Expenses (Quarterly) | 16.22B |
EPS Diluted (Quarterly) | -0.60 |
Gross Profit Margin (Quarterly) | 46.92% |
Profit Margin (Quarterly) | -23.64% |
Earnings Yield | 1.30% |
Operating Earnings Yield | 2.13% |
Normalized Earnings Yield | 3.832 |